James Rider, MD
Cardiovascular Disease · Green Bay, WINPI 1568525988
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $930 of the $1,040 with a category attached, or 89.4%. AstraZeneca accounts for 90.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $975 and has fallen 97.8% since, to $21 in 2025.
Across 7 payments — averaging $148.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$940
- Amgen$22
- Novartis$22
- Teva Pharmaceuticals USA, Inc.$21
- Boehringer Ingelheim$21
- Johnson & Johnson$14
Across 170 payments — averaging $2284.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$250K
- Boehringer Ingelheim Pharma GmbH & Co.kg$44K
- Boehringer Ingelheim International GmbH$37K
- Kowa Research Institute, Inc.$33K
- AstraZeneca$11K
- Esperion Therapeutics, Inc.$6K
- plus $7K from 2 others
What the payments were for
- Consulting fees$93089%
- Food & beverage$10010%
- Education$101%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $940 |
| Amgen | 1 | $22 |
| Novartis | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $21 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$930
How this compares
$1,040 in reported general payments places this provider in the 55th percentile of 322 cardiovascular disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 57 | $68,048 |
| EntrestoSacubitril/Valsartan | 28 | $34,867 |
| Repatha SureclickEvolocumab | 21 | $13,487 |
| Praluent PenAlirocumab | 16 | $11,943 |
| FarxigaDapagliflozin Propanediol | 11 | $10,870 |
| JardianceEmpagliflozin | 14 | $9,406 |
| Warfarin Sodium | 74 | $1,024 |
| Metoprolol Succinate | 56 | $828 |
| Rosuvastatin Calcium | 39 | $653 |
| Losartan Potassium | 64 | $631 |
| Atorvastatin Calcium | 84 | $579 |
| Carvedilol | 65 | $560 |
| Ezetimibe | 15 | $516 |
| Amlodipine Besylate | 43 | $406 |
| Metoprolol Tartrate | 36 | $355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $22 | $34,86728 claims |
| AstraZenecaFarxiga | $940 | $10,87011 claims |
| Boehringer IngelheimJardiance | $21 | $9,40614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 322 cardiovascular disease providers in Wisconsin.
Other cardiovascular disease in Green Bay
- Arbind ChaudharyGreen Bay$42K
- Abdul SafadiGreen Bay$28K
- Anas SarhanGreen Bay$25K
- Kristofer DoshGreen Bay$9K
- Subhashish AgarwalBrookfield$378K
- Lee BibloMilwaukee$280K
- David GrambowMilwaukee$267K
- Joshua LibermanMequon$230K
- Imdad AhmedJanesville$164K
- David MurdockWausau$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.